Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require treatment for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumours.
Pearl of the day medication: Belzutifan (Welireg)
Indication: Belzutif is a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau disease who require treatment for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, not requiring no immediate surgery.
Overview:
- Dosage: The recommended dosage of belzutifanis is 120 mg taken orally once daily with or without food.
- Dosage forms:Tablets 40mg.
- Adverse Events (AE): The most common AEs (≥ 25%), including laboratory abnormalities, were hemoglobin decreased, anemia, fatigue, creatinine increased, headache, dizziness, increased blood sugar and nausea.
- Action mechanism: Belzutifan is an inhibitor of hypoxia-induced factor 2 alpha (HIF-2α). HIF-2α is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia.
- Maker: Merck
Sources: